Polyrizon Ltd. (NASDAQ: PLRZ) shares began Wednesday lower. The Israeli-based company, a development-stage biotech concern specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
“With the execution of these final agreements,” read this morning’s news release, “Polyrizon has completed the contracting with all five U.S. clinical sites selected for the study, marking an important operational milestone and moves the NASARIX™ program into study execution.” The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The study is designed to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either NASARIX™ Allergy Blocker or an isotonic saline nasal spray control.
The study’s primary efficacy endpoint will evaluate the difference between the treatment groups in mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability.
PLRZ shares capsized 74 cents, or 5.1%, to $13.62.
